Thu. 15 Feb 2024, 8:02am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(1.32) by 41.67 percent. The company reported quarterly sales of $346.00 million which missed the analyst consensus estimate of $442.90 million by 21.88 percent. This is a 3.27 percent increase over sales of $335.04 million the same period last year.